Agenus Inc. is a biotechnology company based in Lexington, Massachusetts, USA, focused on immunotherapy, particularly immuno-oncology, which utilizes the immune system to control or cure cancer. The company is involved in developing checkpoint modulators (CPMs), patient-specific anti-cancer vaccines, and adjuvants designed for use with various vaccines.

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

COM:AGENUSBIO

Agenus Inc.

Last Close

2.86

22/11 21:00

Market Cap

66.82M

Beta: -

Volume Today

1.08M

Avg: -

Analysis Not Available